Benjumin Hsu1, Robert G Cumming1, Vasant Hirani1, Fiona M Blyth1, Vasi Naganathan1, David G Le Couteur1, Markus J Seibel1, Louise M Waite1, David J Handelsman1. 1. ANZAC Research Institute (B.H., R.G.C., D.G.L.C., M.H.S., D.J.H.), University of Sydney and Concord Hospital, Sydney, New South Wales, Australia 2139; School of Public Health (B.H., R.G.C., V.H.), University of Sydney, Sydney, New South Wales, Australia 2006; and Centre of Education and Research on Ageing (R.G.C., V.H., F.M.B., V.N., L.M.W.), University of Sydney and Concord Hospital, Sydney, New South Wales, Australia 2139.
Abstract
CONTEXT: Although androgen status decreases with aging in unselected men, the contemporaneous relationship over time between circulating hormones and androgen-sensitive outcomes has not been reported. OBJECTIVE: To investigate the temporal relationships between age-specific androgen status and muscle (mass, strength), hemoglobin, and prostate-specific antigen (PSA). DESIGN, SETTING AND PARTICIPANTS: Men aged 70 years and older from the Concord Health and Ageing in Men Project study were assessed at baseline (2005–2007; n = 1705) and at 2-year (n = 1367) and 5-year follow-up (n = 958). MAIN OUTCOME MEASURES: At all assessments, serum T, dihydrotestosterone (DHT), estradiol (E2), and estrone (E1) were measured by liquid chromatography-tandem mass spectrometry, and serum SHBG, LH, and FSH were measured by immunoassay together with calculation of free T (cFT). Muscle mass, strength of upper (hand grip) and lower (walking speed) limbs, hemoglobin, and prostate size (serum PSA) were measured. RESULTS: Serum hormones showed longitudinal, within-man decreases in serum T (−2.6%/y), DHT (−2.6%/y), E1 (−3.2%/y), and cFT (−2.8%/y) but increases in serum E2 (2.6%/y), SHBG (1.3%/y), LH (1.9%/y), and FSH (1.8%/y). Significant positive correlation was observed between changes in serum T with muscle mass, strength, and hemoglobin but not with PSA across the three time-points. Changes in serum DHT, cFT, and E1 had significant correlation with muscle mass, strength, and hemoglobin, but not with PSA. CONCLUSIONS: These extended observational data are consistent with the impact of reduced androgen status on some somatic features of male aging. However, they do not exclude reverse causality or independent effects of aging on both androgen status and androgen-sensitive outcomes.
CONTEXT: Although androgen status decreases with aging in unselected men, the contemporaneous relationship over time between circulating hormones and androgen-sensitive outcomes has not been reported. OBJECTIVE: To investigate the temporal relationships between age-specific androgen status and muscle (mass, strength), hemoglobin, and prostate-specific antigen (PSA). DESIGN, SETTING AND PARTICIPANTS: Men aged 70 years and older from the Concord Health and Ageing in Men Project study were assessed at baseline (2005–2007; n = 1705) and at 2-year (n = 1367) and 5-year follow-up (n = 958). MAIN OUTCOME MEASURES: At all assessments, serum T, dihydrotestosterone (DHT), estradiol (E2), and estrone (E1) were measured by liquid chromatography-tandem mass spectrometry, and serum SHBG, LH, and FSH were measured by immunoassay together with calculation of free T (cFT). Muscle mass, strength of upper (hand grip) and lower (walking speed) limbs, hemoglobin, and prostate size (serum PSA) were measured. RESULTS: Serum hormones showed longitudinal, within-man decreases in serum T (−2.6%/y), DHT (−2.6%/y), E1 (−3.2%/y), and cFT (−2.8%/y) but increases in serum E2 (2.6%/y), SHBG (1.3%/y), LH (1.9%/y), and FSH (1.8%/y). Significant positive correlation was observed between changes in serum T with muscle mass, strength, and hemoglobin but not with PSA across the three time-points. Changes in serum DHT, cFT, and E1 had significant correlation with muscle mass, strength, and hemoglobin, but not with PSA. CONCLUSIONS: These extended observational data are consistent with the impact of reduced androgen status on some somatic features of male aging. However, they do not exclude reverse causality or independent effects of aging on both androgen status and androgen-sensitive outcomes.
Authors: Rakibul M Islam; Robin J Bell; David J Handelsman; Penelope J Robinson; Rory Wolfe; Susan R Davis Journal: Clin Endocrinol (Oxf) Date: 2021-01-02 Impact factor: 3.478
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi Journal: Nat Rev Dis Primers Date: 2019-05-30 Impact factor: 52.329
Authors: Susan R Davis; Robin J Bell; Penelope J Robinson; David J Handelsman; Tom Gilbert; James Phung; Reena Desai; Jessica E Lockery; Robyn L Woods; Rory S Wolfe; Christopher M Reid; Mark R Nelson; Anne M Murray; John J McNeil Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Visalini Nair-Shalliker; Sam Egger; Agata Chrzanowska; Rebecca Mason; Louise Waite; David Le Couteur; Markus J Seibel; David J Handelsman; Robert Cumming; David P Smith; Bruce K Armstrong Journal: PLoS One Date: 2018-03-08 Impact factor: 3.240
Authors: Rakibul M Islam; Robin J Bell; David J Handelsman; John J McNeil; Mark R Nelson; Christopher M Reid; Andrew M Tonkin; Rory S Wolfe; Robyn L Woods; Susan R Davis Journal: Lancet Healthy Longev Date: 2022-02-07
Authors: Bu Beng Yeap; Ross James Marriott; Robert J Adams; Leen Antonio; Christie M Ballantyne; Shalender Bhasin; Peggy M Cawthon; David John Couper; Adrian S Dobs; Leon Flicker; Magnus Karlsson; Sean A Martin; Alvin M Matsumoto; Dan Mellström; Paul E Norman; Claes Ohlsson; Eric S Orwoll; Terence W O'Neill; Molly M Shores; Thomas G Travison; Dirk Vanderschueren; Gary A Wittert; Frederick C W Wu; Kevin Murray Journal: BMJ Open Date: 2020-05-11 Impact factor: 2.692